Fibrinogen Concentrates Market – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2034
Overview
Fibrinogen Concentrates Market value is projected to reach US$ 5.67 Bn. at the end of the forecast period and it is expected to grow at the CAGR of 5.9%.
Fibrinogen Concentrates Market Definition:
The main contributing factor to this market is the growing incidence of bleeding disorders and an upsurge in the number of approvals associated to fibrinogen concentrate. The congenital fibrinogen deficiency segment is projected to grow at a CAGR of xx % for the duration of the forecast duration. The North America region was valued US$ xx Mn in 2025 and is expected to reach US$ xx Mn by 2034.
Fibrinogen Concentrates Market Growth Analysis
To know about the Research Methodology :- Request Free Sample Report
Fibrinogen Concentrates Market Dynamics
Fibrinogen is a soluble plasma glycoprotein. It is one of the blood clotting factors which are vital for blood clot formation. Fibrinogen pays attention is detailed for the treatment of acute bleeding incidents in patients with congenital fibrinogen deficiency, with afibrinogenemia and hypofibrinogenemia. It is a glycoprotein in vertebrates used as a medicinal drug for a blood disorder, which helps within the formation of blood clots. In severely bleeding patients, fibrinogen concentrate drastically improves whole blood clot firmness and decreases the postoperative transfusion necessities. The factors together with the upsurge in the use of fibrinogen pay attention to bleeding patients and for the treatment of congenital deficiencies propel the growth of the global market.
Besides, the upward thrust in consciousness and issues referring to the health enhance the growth of the market. The upsurges in demand for fibrinogen concentrates, a rise in the range of instances of bleeding issues, and the increase in obtainability of fibrinogen products are the main factors anticipated to thrust the global fibrinogen concentrates marketplace.
However, certain negative reactions including arterial thrombosis, chills, dyspnea, nausea, vomiting, and pulmonary embolism confine the growth.
Fibrinogen concentrates Market Segment analysis
Based at the Application, the congenital fibrinogen deficiency segment is projected to grow at a CAGR of xx% for the duration of the forecast duration. Congenital Fibrinogen Deficiency is predicted to register a higher increase in the fibrinogen concentrate marketplace as a result of the better occurrence of hemophilia and improvement in products associated with fibrinogen. According to the National Hemophilia Foundation, the worldwide prevalence of hemophilia is not well known, but estimated at more than 400,000 people. Nearly 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment market. Biotest's fibrinogen concentrate is presently being investigated clinically in a multinational segment I/III trial in sufferers with congenital fibrinogen deficiency. For the acquired fibrinogen deficiency Biotest conducts a Phase III examine in multiple European nations in patients with high blood loss throughout spine surgery. Therefore, the growing occurrence of bleeding problems and the safety and efficiency of human fibrinogen concentrate is anticipated to thrust the fibrinogen concentrate market growth in this segment.
Fibrinogen concentrates Market Regional analysis
North America is projected to account for the largest market share during the forecast period. The U.S. is expected to account for the largest market share in North America, followed by Canada. Approximately 18,000 people are living with hemophilia in the United States. The market within the region is predicted to be compelled by an upsurge in focus on developing new treatment plans for rare blooding clotting issues and refining access to orphan drugs which are indicated for the treatment of rare diseases.
Europe is probable to gain market share during the forecast length because of an upsurge in the number of market players presenting plasma-derived fibrinogen and an increase in the acceptance of new treatments in Germany, France, and the U.K. the fibrinogen concentrates. Acquired hemophilia, an unprecedented autoimmune disorder, is moderately predominant in the aged populace.
Octapharma has introduced the booklet of recent information demonstrating that the fibrinogen pay attention fibryga® is an effective opportunity to cryoprecipitate for patients with severe bleeding at some stage in cardiac surgery. The statistics have been recently posted inside the Journal of the American Medical Association (JAMA) in 31st Oct 2019.
Fibrinogen Concentrates Market Recent industry developments
15 March 2018 -Biotest AG today announces that the first patient in the pivotal phase III study in patients with acquired fibrinogen deficiency (study no. 995) has been treated.
The objective of the report is to present a comprehensive analysis of the Global Fibrinogen concentrates Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.
The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Fibrinogen concentrates Market dynamics; structure by analysing the market segments and projects the Global Fibrinogen concentrates Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Fibrinogen concentrates Market make the report investor’s guide.
Fibrinogen Concentrates Market Recent Industry Developments
| Date | Company | Development | Impact |
|---|---|---|---|
| 12 January 2026 | Octapharma | Octapharma launched the new 2-gram Fibryga kit featuring a nextaro reconstitution device in the U.S. for acquired fibrinogen deficiency. | This introduction significantly improves preparation speed and dosing precision during critical bleeding management scenarios. |
| 15 June 2025 | Grifols | Grifols published positive results from its Phase 3 clinical trial for fibrinogen in The Lancet's eClinicalMedicine. | The data reinforces clinical confidence, supporting expanded adoption in surgical and trauma hemostasis. |
| 10 December 2025 | Grifols Egypt | Grifols Egypt advanced its national framework targeting an estimated contribution of 55 million euros to the local economy while securing plasma-derived self-sufficiency. | The initiative greatly enhances regional supply chain resilience for essential coagulation factor therapies. |
| 20 November 2025 | Octapharma | Octapharma partnered with the University of Colorado Anschutz Medical Campus to back a $29 million research grant focused on trauma care applications. | This funding accelerates clinical insights into targeted point-of-care bleeding management in emergency settings. |
Fibrinogen concentrates Market Scope: Inquire before buying
| Fibrinogen Concentrates Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | US $ 3.39 Bn. |
| Forecast Period 2026 to 2034 CAGR: | 5.9% | Market Size in 2034: | US $ 5.67 Bn. |
| Segments Covered: | by Application | Congenital Fibrinogen Deficiency Surgical Procedures |
|
| by Type | Human Fibrinogen Concentrates Animal Fibrinogen Concentrates |
||
Fibrinogen concentrates Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Fibrinogen Concentrates Market, Key Players:
1. CSL Behring
2. Octapharma AG
3. LFB Group
4. Grifols, S.A.
5. Hualan Biological Engineering
6. Kedrion Biopharma
7. Shanghai RAAS Blood Products
8. Biotest AG
9. Baxter International
10. GC Pharma (Green Cross)
11. Prothya Biosolutions
12. Sanquin Plasma Products
13. Bio Products Laboratory (BPL)
14. Bharat Serums & Vaccines
15. Intas Pharmaceuticals
16. Jiangxi Boya Biological
17. Takeda Pharmaceutical Company
18. Sinopharm (CNPGC)
19. Reliance Life Sciences
20. China Resources Boya Biopharmaceutical Group
21. Kedrion S.p.A.
22. Emergent BioSolutions
23. CSL Limited
24. Albumin Bioscience
25. Asahi Kasei Pharma
26. Japan Blood Products Organization
27. China Biologic Products Holdings
28. Vistagen Therapeutics
29. ProMetic Life Sciences
30. Bio-Rad Laboratories
Frequently Asked Questions:
1] What segments are covered in the Global Fibrinogen Concentrates Market report?
Ans. The segments covered in the Market report are based on Application and Type
2] Which region is expected to hold the highest share in the Global Market?
Ans. The North American region is expected to hold the highest share in Market.
3] What is the market size of the Global Market by 2034?
Ans. The market size of the Global Market by 2034 is expected to reach US$ 5.67 Bn.
4] What is the forecast period for the Global Market?
Ans. The forecast period for the Market is 2026-2034.
5] What was the market size of the Global Market in 2025?
Ans. The market size of the Global Market in 2025 was valued at US$ 3.39 Bn.